Snipr Biome chose clinical debut in CRISPR-ready USA

Danish CRISPR company Snipr Biome is betting on the US following the FDA's thumbs-up to begin phase I clinical testing of its first drug candidate, says CEO Christian Grøndahl, who is in final talks with two US-based contractors for the trial.

Christian Grøndahl, CEO at Snipr Biome | Photo: Snipr Biome/PR

Snipr Biome has great expectations for 2022 following the US Food and Drug Administration (FDA) approval of the company's application to initiate a phase I clinical trial with its first development candidate, which will be conducted in the US.

CEO Christian Grøndahl expects that Snipr Biome will begin the study in the first six months of the year, and that the company will have the first results before the end of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs